Archives
-
Bazedoxifene: From ER Binding to Bone Assays
2026-09-05
Bazedoxifene is a selective estrogen receptor modulator whose value in osteoporosis research depends on matching molecular, cellular, and skeletal endpoints. This guide translates clinical evidence into a practical assay strategy for studying bone mineral density enhancement and postmenopausal osteoporosis.
-
EdU Imaging Kits (Cy3) for S-Phase Analysis
2026-09-05
EdU Imaging Kits (Cy3) combine click-chemistry specificity with fluorescence microscopy and flow cytometry flexibility for measuring DNA synthesis. The workflow is especially useful when researchers need to preserve morphology and antigen-binding sites while comparing developmental, regenerative, cancer, or genotoxic responses.
-
Sulfisomidine: hPON1 Assay & Antibacterial Workflows
2026-09-04
Sulfisomidine is a dual-purpose research reagent for probing bacterial folate metabolism and mixed-type inhibition of human serum paraoxonase 1. This workflow-focused guide shows how to prepare, dose, fit, and troubleshoot Sulfisomidine assays while preserving interpretive value across enzyme, cell, and environmental studies.
-
CNQX in Reliable Excitotoxicity Assays
2026-09-04
CNQX, also known as 6-cyano-7-nitroquinoxaline-2,3-dione, helps researchers distinguish AMPA/kainate-driven excitation from NMDA-dependent and non-glutamatergic effects in neuronal viability and cytotoxicity workflows. This scenario-based guide explains how the documented formulation, potency, solubility, and storage specifications of SKU B6222 support practical assay standardization.
-
SmMAPK3–SmRAS1 Phosphorylation in Salvia miltiorrhiza
2026-09-03
The reference study identifies a salicylic acid-responsive SmMAPK3–SmRAS1 signaling module that controls salvianolic acid accumulation through phosphorylation of SmRAS1 at Ser178. Its combination of transgenic hairy roots, interaction screening, kinase assays, and coexpression experiments provides a mechanistic framework for improving phenolic-acid production through post-translational regulation.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-02
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines immune challenges with targeted metabolic intervention and cytokine measurement. The workflow preserves the complexity of human blood while improving comparability for cohort-scale immunometabolism and metabolic disorder research.
-
EMD638683: SGK1 Inhibitor Evidence
2026-09-02
EMD638683 is a selective SGK1 inhibitor that suppresses SGK-dependent NDRG1 phosphorylation and supports mechanistic studies of vascular stiffness, tumor biology, and cell survival. Evidence spans biochemical, cellular, mouse, and endothelial models, but the compound remains a research reagent rather than a validated clinical treatment.
-
Hoechst 33258 for KRas–TNT Assay Design
2026-09-01
Learn how Hoechst 33258, a bis-benzimide DNA stain, can strengthen KRas tunneling-nanotube studies through nuclear registration, cell-state control, and orthogonal validation. This guide emphasizes interpretation safeguards rather than treating nuclear fluorescence as evidence of oncogenic protein transfer.
-
SNS-032: A CDK Inhibitor for Mechanistic Assays
2026-09-01
SNS-032 (BMS-387032) is a potent CDK2, CDK7, and CDK9 inhibitor for dissecting cell-cycle and transcriptional mechanisms. This article connects its phospho-RNA Pol II readouts to rigorous cancer assays and explains why recent SARS-CoV-2 host-factor research should be interpreted as a cross-domain hypothesis, not direct evidence for SNS-032 antiviral activity.
-
SCUBE3 Antibody Targeting in Cancer Progression
2026-08-31
The reference study identifies secreted SCUBE3 as a multifunctional driver of tumor growth, therapy resistance, and immune suppression. Its neutralizing antibody blocks SCUBE3-associated receptor signaling, reduces FOXR2 and c-Myc activity, restores immune-related gene expression, and suppresses tumors in preclinical models.
-
Anagliptin (SK-0403) for DPP-4 and Vascular Assays
2026-08-31
Anagliptin (SK-0403) supports a two-layer research strategy: biochemical DPP-4 inhibition assays for glycemic-control biology and organ-bath experiments for vascular mechanism discovery. Its reported 3.8 nM DPP-4 IC50 and distinctive Kv channel–SERCA pump signal make it useful for connecting metabolic pharmacology with smooth-muscle physiology.
-
I-BET-762: From BET Inhibition to Ferroptosis
2026-08-30
I-BET-762 connects selective BET inhibition with two translational priorities: inflammatory gene control and ferroptosis sensitization. This thought-leadership analysis interprets the mechanistic evidence, outlines a disciplined validation workflow, and defines where the compound can add value beyond conventional BET inhibitor product pages.
-
Anti-Diabetic Drugs and Fracture Risk: Network Evidence
2026-08-29
This systematic review and network meta-analysis integrated 117 randomized trials to compare fracture outcomes across individual anti-diabetic drugs in people with type 2 diabetes. Although trelagliptin was associated with higher fracture risk and voglibose and albiglutide with lower risk, most agents—including ertugliflozin—did not differ significantly from comparators, highlighting the limits of drug-specific conclusions from randomized trial networks.
-
Ginsenoside Rg1 Neuroprotection Workflow
2026-08-28
Build a reproducible Ginsenoside Rg1 workflow around anesthesia-associated neuroimmune dysfunction, gut barrier integrity, behavior, and synaptic physiology. This triterpene saponin is especially useful when pharmacological rescue is paired with Treg-dependency testing rather than relying on a single inflammatory endpoint.
-
Staurosporine Workflows for Cancer Research
2026-08-28
Staurosporine enables controlled kinase-pathway perturbation, apoptosis modeling, and exploratory angiogenesis studies in cancer research. This workflow-focused guide explains how to prepare DMSO stocks, separate acute signaling effects from cell death, and troubleshoot concentration, timing, and assay-specific variability.